Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
A Clinical Investigation of the Copeland™ Humeral Resurfacing Head
This study is enrolling participants by invitation only.
Sponsored by: Biomet Orthopedics, LLC
Information provided by: Biomet, Inc.
ClinicalTrials.gov Identifier: NCT00698750
  Purpose

The purpose of this study is to perform a five-year, prospective evaluation of the Copeland™ Humeral Resurfacing Head Prosthesis for outcome and durability. Relief of pain and restoration of function will determine long-term clinical outcome while durability will be measured by the absence of revisions.


Condition
Osteoarthritis
Rheumatoid Arthritis
Avascular Necrosis
Humeral Fractures

MedlinePlus related topics: Fractures Osteoarthritis Osteonecrosis Rheumatoid Arthritis
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: A Prospective, Non-Controlled, Clinical Investigation of the Copeland™ Humeral Resurfacing Head

Further study details as provided by Biomet, Inc.:

Primary Outcome Measures:
  • ASES Assessment [ Time Frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years ] [ Designated as safety issue: No ]
  • X-rays [ Time Frame: 6 months, 1 year, 2 years, 3 years, 4 years, 5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of revision or removals [ Time Frame: Any time ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 160
Study Start Date: April 2004
Estimated Study Completion Date: April 2015
Estimated Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts
Copeland™ Humeral Resurfacing Head
Copeland™ Humeral Resurfacing Head

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients requiring humeral resurfacing.

Criteria

Inclusion Criteria:

  • Non-inflammatory degenerative joint disease including osteoarthritis and avascular necrosis.
  • Rheumatoid arthritis
  • Correction of functional deformity
  • Reconstructable Rotator Cuff
  • Treatment of acute fracture of the humeral head
  • Traumatic arthritis

Exclusion Criteria:

  • Patients less than 18 years.
  • Patients with rapid joint destruction, osteomalacia, osteoporosis, or marked bone loss, which would preclude proper fixation of the prosthesis.
  • Patients with marked bone loss apparent on roentgenogram.
  • Metabolic disorders, which may impair bone formation.
  • Patients who are pregnant.
  • Patients with an active or suspected infection in or around the shoulder or distant foci of infections, which may spread to the implant site.
  • Patients with severe instability or deformity of the ligaments and/or surrounding soft tissue, which would prelude stability of the prosthesis.
  • Patients who have had revision procedures where other devices or treatments have failed.
  • Patients with a highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, neoplastic disease, etc).
  • Patients unwilling or unable to comply with a rehabilitation program for a cemented or cementless partial or total shoulder replacement or who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol.
  • Patients with previous shoulder surgery or conditions that may interfere with the partial or total shoulder replacement's survival or outcome.
  • Patients who qualify for inclusion in the study, but refuse consent to participate in the study.
  • Patients who have had a partial or total shoulder arthroplasty on the contralateral shoulder within the last year.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00698750

Sponsors and Collaborators
Biomet Orthopedics, LLC
Investigators
Study Director: Kenneth J Beres, MD Director, Clinical Research, Biomet Orthopedics, LLC
  More Information

Responsible Party: Biomet Orthopedics, LLC ( Kenneth Beres, MD Director Clinical Research )
Study ID Numbers: Biomet 12381-30
Study First Received: June 13, 2008
Last Updated: January 8, 2009
ClinicalTrials.gov Identifier: NCT00698750  
Health Authority: United States: Institutional Review Board

Keywords provided by Biomet, Inc.:
Fractured Humeral Head
Traumatic Arthritis
Resurfacing Shoulder
Shoulder Replacement
Shoulder Arthritis

Study placed in the following topic categories:
Autoimmune Diseases
Osteonecrosis
Osteoarthritis
Joint Diseases
Fractures, Bone
Wounds and Injuries
Arthritis, Rheumatoid
Disorders of Environmental Origin
Humeral Fractures
Rheumatic Diseases
Bone Diseases
Arm Injuries
Necrosis
Musculoskeletal Diseases
Arthritis
Connective Tissue Diseases

Additional relevant MeSH terms:
Pathologic Processes
Immune System Diseases

ClinicalTrials.gov processed this record on January 16, 2009